| Degraded DNA may induce discordance of KRAS status between primary colorectal cancer and corresponding liver metastases. | |
| | |
MedLine Citation:
|
PMID: 23299277 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: KRAS mutation is widely accepted as a strong, negative predictive marker for anti-epidermal growth factor receptor antibodies, including cetuximab and panitumumab. Previous reports demonstrated approximately 100 % concordance of KRAS status between primary colorectal cancer and liver metastases; however, mismatched KRAS status still occurs. METHODS: KRAS status was evaluated in 105 pairs of formalin-fixed primary colorectal cancer and corresponding liver metastases specimens by direct sequencing. DNA quality of patients displaying mismatched KRAS status between primary tumors and metastases was assessed using a Bioanalyzer. RESULTS: KRAS status was successfully analyzed in 90/105 patients (85.7 %). The concordance rate between primary tumors and metastases was 88.2 % in synchronous metastases (n = 76) and 100 % in metachronous metastases (n = 14). Discordance in KRAS status was observed in nine patients. Independent method validation revealed only five samples showed the same KRAS status between the two methods. DNA quality assessment by a Bioanalyzer revealed that the median length of DNA samples in the peak concentration of the mismatched group was significantly shorter than those in the control group (153.5 vs 276.5 bp, P = 0.0059). In addition, the median value of the percentage of degraded DNA (0-200 bp) in each sample in the mismatched group was significantly higher than the control group (35.5 vs 22 %, P = 0.020). These data suggest that the discordant results for these nine patients (18 samples) were due to low quality DNA, which may obscure polymerase chain reaction analysis, affecting sequencing reliability. CONCLUSION: Quality control and assurance of KRAS genotyping is critical, and standardization of the methodology is warranted. |
| | |
Authors:
|
Yuka Kaneko; Hidekazu Kuramochi; Go Nakajima; Yuji Inoue; Masakazu Yamamoto |
Related Documents
:
|
23121567 - Deciphering the epigenetic code: an overview of dna methylation analysis methods. 23111197 - Multiplex ligation-dependent probe amplification (mlpa) in tumor diagnostics and progno... 6788357 - Dna replication and unscheduled dna synthesis in lungs of mice exposed to cigarette smoke. 8127657 - Major oxidative products of cytosine, 5-hydroxycytosine and 5-hydroxyuracil, exhibit se... 16115177 - Dna analysis and dna ploidy in gastric cancer and gastric precancerous lesions. 16741237 - Identification of the dna bases of a dnase i footprint by the use of dye primer sequenc... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-9 |
Journal Detail:
|
Title: International journal of clinical oncology Volume: - ISSN: 1437-7772 ISO Abbreviation: Int. J. Clin. Oncol. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9616295 Medline TA: Int J Clin Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Gastroenterological Surgery, Tokyo Women's Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: DBC1 is over-expressed and associated with poor prognosis in colorectal cancer.
Next Document: Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patient...